Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,277.00 JPY | +0.24% |
|
-1.00% | -5.56% |
Feb. 04 | Mitsui Chemicals Inc- Commencing Tender Offer For DNA Chip Research | RE |
Feb. 03 | Mitsui Chemicals, Inc., Q3 2025 Earnings Call, Feb 04, 2025 |
Fiscal Period: March | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1,339B | 1,212B | 1,613B | 1,880B | 1,750B | |||||
Total Revenues | 1,339B | 1,212B | 1,613B | 1,880B | 1,750B | |||||
Cost of Goods Sold, Total | 1,042B | 918B | 1,234B | 1,498B | 1,379B | |||||
Gross Profit | 297B | 294B | 379B | 381B | 371B | |||||
Selling General & Admin Expenses, Total | 189B | 166B | 188B | 226B | 221B | |||||
Provision for Bad Debts | 3.3B | 2.56B | 7.31B | 7.79B | 2.77B | |||||
R&D Expenses | 36.37B | 33.8B | 38.12B | 42.95B | 44.7B | |||||
Depreciation & Amortization - (IS) | - | 12.5B | 12.95B | 15.92B | 17.19B | |||||
Other Operating Expenses | - | -1.83B | -690M | -1.61B | -525M | |||||
Other Operating Expenses, Total | 228B | 213B | 246B | 291B | 285B | |||||
Operating Income | 68.93B | 81.13B | 133B | 90.73B | 85.9B | |||||
Interest Expense, Total | -5.5B | -4.81B | -4.08B | -6.08B | -7.87B | |||||
Interest And Investment Income | 4.83B | 2.15B | 2.46B | 5.01B | 6.31B | |||||
Net Interest Expenses | -674M | -2.66B | -1.63B | -1.07B | -1.55B | |||||
Income (Loss) On Equity Invest. | 3.16B | 5.99B | 25.82B | 21.69B | 12.3B | |||||
Currency Exchange Gains (Loss) | -3M | - | - | - | 6.92B | |||||
Other Non Operating Income (Expenses) | -5.9B | 1.75B | 3.28B | -2.59B | -3.08B | |||||
EBT, Excl. Unusual Items | 65.52B | 86.2B | 160B | 109B | 100B | |||||
Impairment of Goodwill | - | - | 7.25B | - | 939M | |||||
Gain (Loss) On Sale Of Investments | -11.94B | -3M | -4.98B | 23.12B | 2.23B | |||||
Gain (Loss) On Sale Of Assets | -3.78B | -3.39B | -5.05B | -7.14B | -6.17B | |||||
Asset Writedown | -2.51B | -8.05B | -16.18B | -7.46B | -24.16B | |||||
Other Unusual Items | 21.17B | -515M | -1M | -14M | - | |||||
EBT, Incl. Unusual Items | 68.46B | 74.24B | 141B | 117B | 73.33B | |||||
Income Tax Expense | 22.17B | 10.02B | 22.72B | 27.14B | 19.56B | |||||
Earnings From Continuing Operations | 46.29B | 64.22B | 119B | 90.14B | 53.78B | |||||
Net Income to Company | 46.29B | 64.22B | 119B | 90.14B | 53.78B | |||||
Minority Interest | -8.34B | -6.35B | -8.56B | -7.2B | -3.78B | |||||
Net Income - (IS) | 37.94B | 57.87B | 110B | 82.94B | 50B | |||||
Net Income to Common Incl Extra Items | 37.94B | 57.87B | 110B | 82.94B | 50B | |||||
Net Income to Common Excl. Extra Items | 37.94B | 57.87B | 110B | 82.94B | 50B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 194.94 | 298 | 565.45 | 431.17 | 262.99 | |||||
Basic EPS - Continuing Operations | 194.94 | 298 | 565.45 | 431.17 | 262.99 | |||||
Basic Weighted Average Shares Outstanding | 195M | 194M | 195M | 192M | 190M | |||||
Net EPS - Diluted | 194.94 | 298 | 565.45 | 431.17 | 262.99 | |||||
Diluted EPS - Continuing Operations | 194.94 | 298 | 565.45 | 431.17 | 262.99 | |||||
Diluted Weighted Average Shares Outstanding | 195M | 194M | 195M | 192M | 190M | |||||
Normalized Basic EPS | 167.5 | 244.75 | 470.85 | 315.95 | 310.47 | |||||
Normalized Diluted EPS | 167.5 | 244.75 | 470.85 | 315.95 | 310.47 | |||||
Dividend Per Share | 100 | 100 | 115 | 120 | 140 | |||||
Payout Ratio | 51.42 | 33.43 | 18.66 | 29.13 | 49.43 | |||||
American Depositary Receipts Ratio (ADR) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |||||
Supplemental Items | ||||||||||
EBITDA | 121B | 158B | 217B | 183B | 181B | |||||
EBITA | 69.57B | 81.13B | 133B | 90.73B | 85.9B | |||||
EBIT | 68.93B | 81.13B | 133B | 90.73B | 85.9B | |||||
Effective Tax Rate - (Ratio) | 32.39 | 13.5 | 16.08 | 23.14 | 26.67 | |||||
Normalized Net Income | 32.6B | 47.53B | 91.59B | 60.77B | 59.03B | |||||
Interest Capitalized | - | - | 50M | 83M | 323M | |||||
Non-Cash Pension Expense | 161M | 932M | 692M | 938M | 345M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 58.48B | 58.16B | 68.64B | 77.34B | 71.66B | |||||
Research And Development Expense From Footnotes | 36.37B | 33.8B | 38.1B | 43B | 44.7B |